ArticleProteomics. Clinical applications2009
Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability.
Article in Proteomics. Clinical applications, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- The Effect of Preanalytical Conditions on Blood-Based Inflammation Biomarkers.Journal of proteome research · 2025Article
- Review
- Guidelines on antibody use in physiology research.American journal of physiology. Renal physiology · 2024Article
- Characteristics of the tissue section that influence the staining outcome in immunohistochemistry.Histochemistry and cell biology · 2019Article
- Autopsy Biobanking: Biospecimen Procurement, Integrity, Storage, and Utilization.Methods in molecular biology (Clifton, N.J.) · 2019Review
- Personalization of prostate cancer therapy through phosphoproteomics.Nature reviews. Urology · 2018Review
- Sample handling of gastric tissue and O-glycan alterations in paired gastric cancer and non-tumorigenic tissues.Scientific reports · 2018Article
- Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics.Scientific reports · 2017Article
- A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.Molecular oncology · 2016Article
- Effects of Cold Ischemia on Gene Expression: A Review and Commentary.Biopreservation and biobanking · 2016Review
- Homogenization of tissues via picosecond-infrared laser (PIRL) ablation: Giving a closer view on the in-vivo composition of protein species as compared to mechanical homogenization.Journal of proteomics · 2016Article
- Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery.Microarrays (Basel, Switzerland) · 2015Review
- Phosphoproteomic profiling of tumor tissues identifies HSP27 Ser82 phosphorylation as a robust marker of early ischemia.Scientific reports · 2015Article
- Fixation strategies for retinal immunohistochemistry.Progress in retinal and eye research · 2015Review
- Systems biology of neurodegenerative diseases.Integrative biology : quantitative biosciences from nano to macro · 2015Review
- Reverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use.Microarrays (Basel, Switzerland) · 2015Review
- Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.Cellular oncology (Dordrecht, Netherlands) · 2015Review
- Reverse phase protein arrays: mapping the path towards personalized medicine.Molecular diagnosis & therapy · 2014Review
- Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.Molecular & cellular proteomics : MCP · 2014Article
- The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings.Clinical biochemistry · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Instability of tissue protein biomarkers is a critical issue for molecular profiling. Pre-analytical variables during tissue procurement, such as time delays during which the tissue remains stored at room temperature, can cause significant variability and bias in downstream molecular analysis. Living tissue, ex vivo, goes through a defined stage of reactive changes that begin with oxidative, hypoxic and metabolic stress, and culminate in apoptosis. Depending on the delay time ex vivo, and reactive stage, protein biomarkers, such as signal pathway phosphoproteins will be elevated or suppressed in a manner which does not represent the biomarker levels at the time of excision. Proteomic data documenting reactive tissue protein changes post collection indicate the need to recognize and address tissue stability, preservation of post-translational modifications, and preservation of morphologic features for molecular analysis. Based on the analysis of phosphoproteins, one of the most labile tissue protein biomarkers, we set forth tissue procurement guidelines for clinical research. We propose technical solutions for (i) assessing the state of protein analyte preservation and specimen quality via identification of a panel of natural proteins (surrogate stability markers), and (ii) using multi-purpose fixative solution designed to stabilize, preserve and maintain proteins, nucleic acids, and tissue architecture.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.